AstraZeneca is a global innovation driven biopharmaceutical company pushing the boundaries of science to deliver life-changing medicines.
Science can change our vision of the world and how we deal with the diseases that affect us. The future of treatment for many of today’s diseases lies in uncovering disease mechanisms that are newly emerging or are still to be discovered. Science challenges us to push the limits of what is possible. This is why we put science at the centre of everything we do.
At AstraZeneca South Africa every one of our 160 employees makes a difference to patient lives every day. We are inspired by the things that seem impossible and stimulate continued creativity throughout our organisation, maintaining a culture in which our people feel valued for their ideas and contributions. Ideas that can make a difference in all aspects of our business and to healthcare in South Africa.
Our Johannesburg office serves as a hub of communication between our office-based staff and more than half the company's employees that are directly involved in the promotion of our medicines to healthcare professionals throughout the country.
AstraZeneca South Africa has been working to deliver the best value to patients for over 25 years. Our vision is to transform the lives of patients, ensuring South Africans have access to our innovative medicines.
Northdowns Office Park
17 Georgian Crescent West
BRYANSTON – 2021
Johannesburg – South Africa
Tel:+27 (0) 11 797 6000
Fax: +27 (0) 86 640 1463
Our senior management team
|Barbara Nel||Country President South Africa|
|Dr Donald Ngwira||Medical and Regulatory Affairs Director|
|Ursula Du Preez||Primary Care Strategy Director|
|Mervin Naidoo||Commercial Operations & Business Development Director|
|Smita Ramouthar||Human Resources Lead SA|
|Ruth Field||Market Access Director|
|Reshma Singh||Compliance Senior Manager|
|Attila Kulcsar||Cluster CFO MEA|
|Phumlani Mancapha||Primary Care Sales Director|
|Fatima De Castro||Business Unit Director Oncology|
A WORLD CLASS RESEARCH AND DEVELOPMENT PLAYER
Research & Development
AstraZeneca South Africa has proven its willingness to play a significant role in international R&D through a strong investment in clinical studies, across therapeutic areas, with added value for local doctors and patients.
We have had significant involvement in the rich pipeline of candidate drugs emerging from R&D sites. High quality work with specialists and primary care physicians throughout the country over the past years has resulted in a steady increase of trial work being awarded to the Clinical Research Department in South Africa, which attained key country status in 2000.
Our focus in on adding value, not only to our global company’s research and development programme, but also to the society within which we operate; the institutions and academic centres of medical excellence with whom we have partnered in our work; and finally to the patients whom we serve. South Africa has and continues to participate in many key AstraZeneca projects over all therapeutic areas and is experienced in conducting phase I-IV trials. Currently, AstraZeneca SA is directly involved in 11 trials spanning different therapeutic areas and is working with 140 clinical centres offering new developments to approximately 1305 randomised patients throughout the country. We also conduct CRO led studies locally. (Nov 2018).
Global research studies in our country include:
- DISCOVER: A global real world evidence study of patients with type 2 diabetes mellitus that is moving the frontiers of Medicine.
- COPVAR: A cross-sectional study of patients with severe COPD to assess patient perception of symptom variability in Middle East & Africa countries.
Externally sponsored scientific research studies in South Africa include:
- A prospective, longitudinal, epidemiological study to categorise and electronically capture data of all respiratory patients attending the outpatients clinic at the Charlotte Maxeke Johannesburg Academic Hospital (CMJAH) in South Africa.
The study will aim to electronically capture data as well as attempt to standardise the clinical assessment and therapeutic interventions on all patients attending the various pulmonology outpatient clinics at the CMJAH. The study will also introduce various tools validated for assessment of the different pulmonary disease entities and use these objective scoring systems to assess patient severity and response to therapy.
- Lung function predictive equations for healthy South African children and adults: The Paediatric and Adult African Spirometry Working Group. This study will aim to determine the normal reference equations for spirometry in South African adults and children.
OUR FOCUS AREAS
Unlocking the power of what science can do.
We market medicines that are designed to improve the health and quality of life of patients, focusing on 3 main therapy areas: Respiratory; Cardiovascular, Renal and Metabolism (CVRM) with newer treatments in Type 2 Diabetes Mellitus being our core strength; and Oncology with targeted and immune-oncology therapies being the future portfolio in cancer management.
At AstraZeneca, CVRM is one of our main therapy areas because science continues to uncover commonalities between cardiovascular, renal and metabolic diseases. With this knowledge, we are daring to do things differently by shifting focus from treating patients with a single disease, to addressing overlapping disease areas and risk factors. This is why we have created a distinct approach to care for CVRM – CaReMe. This new approach gives us the chance to save vital time and valuable healthcare resources, and most importantly improve patient lives.
Diabetes is a disease of epidemic scale and an important strategic focus for AstraZeneca. With reportedly nearly 2 million people living with diabetes in South Africa, we are focused on redefining the Type 2 diabetes treatment approach and harnessing complementary mechanisms of action, as well as cardiovascular outcomes benefits.
As facilitators of the CaReMe approach, we make it our responsibility to help healthcare professionals connect the dots, evolve their clinical practice and provide complete, potentially life-saving care for CVRM patients. Our role is to offer healthcare professionals the best possible solutions to enable them to think holistically and work in closer collaboration during everyday care and across individual specialties. Most importantly, it is through partnering with health care professionals that they can protect patients against heart and renal failure, improve health and save the lives of patients in South African living with these diseases.
For more than 40 years we have developed drugs to combat cancer, many of which have increased survival rates for patients around the world. We aim to advance the science of oncology with a combination-focused pipeline set to address the unmet clinical needs in a host of cancers. Our vision is to redefine the cancer treatment paradigm in South Africa.
In South Africa AstraZeneca has a proven track record of working collaboratively and successfully with the Government and health partners to bring medicines for chronic conditions to South African patients in a timely manner and securing expanded access to these medicines via our Phakamisa programme.
Our goal is to establish a leading position in Asthma and Chronic Obstructive Pulmonary Disease (COPD). We aim to bring value to the broader scientific community in South Africa, held redefine standards of care and raise awareness of the ongoing unmet medical need in Asthma and COPD.
AstraZeneca South Africa will continue to optimise clinical practice through a range of differentiated inhaled therapies, novel combinations and devices for asthma and COPD to improve choice and outcomes for patients. Our inhaled treatments are the foundation of our respiratory portfolio in South Africa and core to our business.
OUR INVESTMENT IN CONTINUOUS MEDICAL EDUCATION
- We have a strong scientific team of qualified Medical Doctors and Specialists providing key scientific support, across our key Therapeutic Areas, to our AstraZeneca teams and our customers.
- We collaborate with different medical societies to increase awareness of global management guidelines. We continually explore additional areas for collaboration with medical and pharma societies, with the aim of supporting the education of Health Care Professionals (HCPs).
- We have worked extensively to bring some of the best educational resources and key experts to South Africa to expand scientific education programmes and knowledge sharing amongst HCPs.
- AstraZeneca South Africa utilises live WebEx platforms to host international speakers, bringing international knowledge to the region and combining this with local expertise to promote knowledge sharing.
- The ePD platform in South Africa, provides doctors access to current, relevant content with international and local speakers. An interactive learning experience utilising technology that offers a solution that best suits doctors’ needs and time.
- MyWallet is a CPD management solution. It assists practitioners in keeping track of their CPD points and simplifies access to certificates. MyWallet stores all CPD points collected locally and internationally providing an auditable record of their continuing professional education.
SUPPORTING OUR PATIENTS AND COMMUNITY
At AstraZeneca we work together across global boundaries to make an impact and find answers to challenges.
In South Africa we consider our responsibility to our patients and our community as an integral part of what we do. When we see an opportunity for change we seize it and make it happen, because an opportunity no matter how small can be the start of something big.
Our commitment to improve health outcomes for South African patients extends far beyond our medicines. We offer programmes that advance patient health and access along the care continuum and provide reliable support networks.
Our Phakamisa Oncology programme in South Africa brings together different organisations to help raise awareness of breast & prostate cancer; strengthen healthcare capabilities; and improve access to treatment and support networks.
The vision of the program is to reduce the burden of breast & prostate cancer a on the national health system by the promotion of primary prevention, early detection and access to affordable medicines.
Launched in 2011 to reduce the burden of breast and prostate cancer on the national health system, the programme focuses on 3 key pillars:
- Education – increasing education in the public, patient, and medical communities
- Access – increasing patients’ access to the care they need by providing Navigators who are specially trained to guide patients through the steps of their medical journey, starting from diagnosis to beyond recovery.
- Capacity – collecting data that demonstrates the serious need for increased and properly allocated resources and using this data to advocate for patients, ensuring they receive the healthcare they deserve when battling breast and prostate cancer. Phakamisa also works with doctors and hospitals to build Centres of Excellence, that will educate a variety of healthcare professionals.
A healthier world begins with education to help individuals make informed decisions and navigate available tools and resources.
Our Yes2Life Diabetes Patient Support Programme in South Africa, in partnership with Health Window, offers patients telephonic support on disease education and adherence to medication. The programme also offers face-to-face patient support on prescribed medication and disease management provided by diabetes case managers.
WORKING AT ASTRAZENECA
At AstraZeneca South Africa we are guided in our work by a strong set of values, and we’re resetting expectations of what a bio-pharmaceutical company can be. By truly following the science, we pioneer new methods, new thinking and bring unexpected teams together.
From medical science to sales & marketing, we’re on a mission to turn ideas into life-changing medicines that transform lives.
If you’re inspired by the possibilities of science to make a difference and ready to discover what you can do – join us.
Good governance is crucial to ensuring we are well managed and can deliver our strategic priorities. Our Code of Conduct sets out the ethical standards we expect of everyone who works at AstraZeneca and, along with our global policies, how these are to be translated into consistent actions worldwide.
PATIENT SAFETY AND ADVERSE EVENT REPORTING
The safety of patients who take our medicines is of fundamental importance to AstraZeneca. We continuously work to identify and minimise the risks and maximise the benefits of each of our medicines. A vital aspect of our commitment to patient safety is making sure that accurate up-to-date information is provided to support effective use of our medicines.
If you would like to report an adverse event for an AstraZeneca product, please contact AstraZeneca Safety:
Phone: +27 11 797 6193
Mobile: +27 72 758 7638
Fax: +27 11 797 6019
Digital AE reporting is now available using the link:
Be among our employees who continue to make us an innovation-driven company that stands firmly among the world’s leaders in biopharmaceuticals.
Science compels us to push the boundaries of what is possible. We trust in the potential of ideas and pursue them, alone and with others, until we have transformed the treatment of disease.